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A
common clinical conundrum faces
all U.S. practitioners treating pa-
tients with type 2 diabetes. Today’s
U.S. Food and Drug Administration pre-
scribing guidelines for metformin contra-
indicate its use in men and women with
serum creatinine concentrations $1.5
and $1.4 mg/dL ($132 and $123
mmol/L), respectively. In a patient toler-
atingandcontrolledwiththismedication,
should it automatically be discontinued
as the creatinine rises beyond these cut
points over time? Stopping metformin of-
ten results in poorly controlled glycemia
and/ortheneedforotheragentswiththeir
own adverse-effect proﬁles. Moreover, is
the now widespread use of estimated glo-
merular ﬁltration rate (eGFR) in lieu of
serum creatinine levels creating even
more confusion, especially in those with
abnormalities in one but not the other in-
direct measure of renal function? Indeed,
more than a decade and a half after met-
formin became available in the U.S., de-
bate continues over the best approach in
these settings (1–3). How many patients
are unable to receive this medication on
the basis of guidelines which, although
well intentioned, are somewhat arbitrary
and outdated based on modern assess-
ments of renal status?
ADVANTAGES OF
METFORMIN—T h e r ei ss o m ee v i -
dence that early treatment with metformin
is associated with reduced cardiovascular
morbidity and total mortality in newly
diagnosed type 2 diabetic patients (4).
However, the data come from a small sub-
group of a much larger trial. In contrast,
despite multiple trials of intensive glu-
cose control using a variety of glucose-
lowering strategies, there is a paucity of
data to support speciﬁca d v a n t a g e sw i t h
other agents on cardiovascular outcomes
(5–7).
In the original UK Prospective Di-
abetes Study (UKPDS), 342 overweight
patients with newly diagnosed diabetes
were randomly assigned to metformin
therapy (8). After a median period of 10
years, this subgroup experienced a 39%
(P = 0.010) risk reduction for myocardial
infarction and a 36% reduction for total
mortality(P=0.011)comparedwithcon-
ventional diet treatment. Similar beneﬁts
were not observed in those randomly as-
signed to sulfonylurea or insulin. In an
8.5-year posttrial monitoring study, after
participants no longer were randomly as-
signed to their treatments, individuals
originally assigned to metformin (n =
279) continuedto demonstrate a reduced
risk for both myocardial infarction (rela-
tive risk 33%, P = 0.005) and total mor-
tality (relative risk 27%, P = 0.002) (9).
The latter results are even more impres-
sivewhenoneconsidersthatHbA1clevels
in all initially randomly assigned groups
hadconvergedwithin1yearoffollow-up.
Unlike sulfonylureas, thiazolidine-
diones, and insulin, metformin is weight
neutral (10), which makes it an attractive
choice for obese patients. Furthermore,
the management of type 2 diabetes can
be complicated by hypoglycemia, which
canseriously limit thepursuitofglycemic
control. Here, too, metformin has advan-
tages over insulin and some types of in-
sulin secretagogues; by decreasing excess
hepatic gluconeogenesis without raising
insulin levels, it rarely leads to signiﬁcant
hypoglycemia when used as a monother-
apy (8,11). As a result, metformin is
widely considered an ideal ﬁrst-line agent
for the treatment of type 2 diabetes, as
recommended by several clinical guide-
lines (12–14).
In addition to such beneﬁts, metfor-
min reduces the risk of developing di-
abetes in individuals at high risk for the
disease (15) and has been considered as a
reasonable “off-label” approach in se-
lected individuals for diabetes prevention
(16).
HISTORICAL PERSPECTIVE—De-
spite these proven beneﬁts, metformin
remains contraindicated in a large seg-
ment of the type 2 diabetic population,
largely because of concerns over the rare
adverse effect of lactic acidosis. For these
reasons, the drug has been restricted to
individuals with normal creatinine levels
as a surrogate for renal competence.
Other contraindications (e.g., any signif-
icant hypoxemia, alcoholism, cirrhosis, a
recent radiocontrast study) also increase
the risk for or the consequences of lactic
acidosis,butthesearenotthe topicofthis
review.
Metformin belongs to the biguanide
drug class (previous members include
phenformin and buformin), developed
for lowering glucose in the 1950s. Initial
enthusiasm for biguanides was tempered
over the next two decades by the growing
recognition of their risk of lactic acidosis.
A marked reduction in biguanide use
occurredinthemid-1970sbecausephen-
formin, extensively adopted in clinical
practice, was implicated in a number of
fatal cases of this severe metabolic de-
compensation (17). The association with
lactic acidosis eventually led to its with-
drawalfromthe market.Importantly,lac-
tic acidosis with phenformin seems to
occur ~10–20 times more frequently
than with metformin (18). In contrast to
metformin, modestly raised phenformin
concentrations may reduce peripheral
glucoseoxidationandenhanceperipheral
lactateproduction,whichcanincreasecir-
culating lactate levels. In fact, phenformin
levels correlate with lactate concentration,
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REVIEWwhereas metformin levels do not (19). In
addition, ~10% of European Caucasians
haveaninherentdefectinphenforminhy-
droxylation,whichmayleadtodrugaccu-
mulation and, as a result, elevated lactate
levels (20).
The experience with phenformin re-
sulted in cautious use of metformin in
Europe. In the 1980s, the creatinine cut
points for contraindication to metformin
were considered to be appropriate at 1.4
mg/dL in women and 1.5 mg/dL in men.
Thiswasbasedonthecalculatedabilityto
remove 3 g of metformin (an amount
slightly beyond the maximum daily U.S.
dose) at steady-statelevelswithin 24–48h.
In fact, the ability to comfortably remove
the drug extends up to creatinine levels of
1.8–2.0 mg/dL, but the cut points chosen
were intentionally set lower to ensure that
those patients who may be lost to follow-
up and whose creatinine levels increase
over time would not be at risk for appre-
ciable drug accumulation.
Metformin was not approved in the
U.S. until December of 1994 and was
marketed in 1995. The experience with
phenformin led to judicious labeling and
recommendations for careful monitoring
of adverse events. Its new-drug applica-
tion was the subject of extensive review.
The risk for lactic acidosis was estimated
to be ~3 cases per 100,000 patient-years
based on cases reported from France, the
U.K., and other countries where pharma-
covigilanceinformationwasavailable(21).
SimilarestimateswerequotedfromSweden
(2.4 cases per 100,000 patient-years),
where the number of cases appeared to
be decreasing despite rising clinical use
of metformin. After careful deliberation,
metformin was approved by the U.S.
FoodandDrugAdministration,withlactic
acidosis risk seen as small, although inev-
itable with future widespread availability
of the drug.
CLINICAL PRACTICE
GUIDELINES—The prescribing infor-
mation for metformin in the current label
is explicit with respect to renal contra-
indications, based on serum creatinine
cut points. It proscribes use at or above
the 1.4 and 1.5 mg/dL levels in women
and men, respectively. The recently up-
dated Kidney Disease Outcomes Quality
Initiative guidelines from the National
Kidney Foundation are perfectly consis-
tent with the label (22). Yet, certain U.S.
practice guidelines substantially differ in
their recommendations for metformin
use related to renal status. The annually
updated clinical practice guidelines is-
sued by the American Diabetes Associa-
tion, for example, do not actually discuss
renal thresholds (16) but refer the reader
to a separate consensus statement for pre-
scribing details. This statement, authored
bymembersof theAmericanDiabetes As-
sociation and European Association for
the Study of Diabetes, reports that met-
formin seems safe unless eGFR falls to
,30 mL/min per 1.73 m
2 (12).
Clinical guidelinesoutside ofthe U.S.
incorporate the eGFR for determination
of metformin safety. In the U.K., for
example, prescribing guidelines consider
both creatinine and eGFR for assessing
treatment eligibility. The National Insti-
tute for Health and Clinical Excellence
recommends reviewing the clinical cir-
cumstances when serum creatinine ex-
ceeds 130 mmol/L (1.5 mg/dL) or eGFR
falls below 45 mL/min per 1.73 m
2.T h e
National Institute for Health and Clinical
Excellence further speciﬁes that metfor-
min be stopped if serum creatinine ex-
ceeds 150 mmol/L (1.7 mg/dL) (a higher
threshold than in the U.S.) or eGFR is be-
low 30 mL/min per 1.73 m
2 (14). In con-
trast, the Canadian Diabetes Association
practice guidelines are now based solely
on eGFR, recommending caution with
eGFR ,60 mL/min per 1.73 m
2 and con-
traindicating its use with eGFR ,30
mL/min per 1.73 m
2 (23). The Australian
Diabetes Society practice guidelines simi-
larly recommend against metformin
with eGFR ,30 mL/min per 1.73 m
2
and caution with eGFR 30–45 mL/min
per 1.73 m
2 (24). Thus, although there
is clear recognition that renal failure may
be a risk factor for adverse events with
metformin use, there is signiﬁcant diver-
gence in opinion across the globe regard-
ing the optimal deﬁnition of safety.
METFORMIN
PHARMACOKINETICS—The prin-
cipal reason for carefully setting renal
thresholdsisthatmetforminiseliminated
unchanged primarily by the kidneys.
Thus, one of the most important risk
factors for elevated metformin concentra-
tions(whichareproposed to leadto lactic
acidosis) is the inability to clear the drug
efﬁciently. Metformin has a 50–60% bio-
availability and is absorbed mainly in the
small intestine. It does not appear to bind
appreciably to plasma proteins. The max-
imum plasma concentration is observed
~2 h after oral dosing, typically reaching a
Cmaxof1–2mg/mL(~10mmol/L).Metformin
accumulates in the walls of the small
intestine and salivary glands as well as
inthe kidney (25). Ithas a plasma elimina-
tion half-life of 6.2 h and is renally elimi-
nated both by ﬁltration and active tubular
secretion (26).
In careful experiments, Tucker et al.
(27) studied metformin kinetics in 4
healthy subjects and 12 type 2 diabetic
subjects and found that plasma renal
clearance of metformin highly correlated
with creatinine clearance (CrCl; r = 0.85,
P , 0.001). However, the relationship
between physiological clearance of an ac-
tual oral dose and CrCl was much weaker
(r =0.66,P , 0.01). Therefore, the inves-
tigators postulated that other factors may
impact this relationship, such as perhaps
gastrointestinal absorption of metformin
in patients with renal failure and/or non-
renal clearance of a small amount of the
drug.
Inanotherpharmacokineticstudy(28),
as i n g l e8 5 0 - m gd o s eo fm e t f o r m i nw a s
givento21healthysubjectsand13subjects
withrenalinsufﬁciency(mildtosevere).
In the control group (data presented are
mean6SD)(meanCrCl11268mL/min),
average renal metformin clearance was
636684mL/min,whereasinmildchronic
kidneydisease(CKD)(CrCl61–90mL/min;
mean 73 6 7) clearance was reduced at
3846122mL/min.Themeanrenalclear-
ance of metformin was lower in subjects
with moderate (CrCl 31–60 mL/min; mean
41 6 9) and severe (CrCl 10–30 mL/min;
mean 22 6 6) CKD, measuring 108 6 57
and 130 6 90 mL/min, respectively. Sim-
ilarly, maximum concentration and the
area under the concentration time curve
were increased in individuals with mod-
erateto severeCKDcompared withthose
with mild CKD or normal renal function.
Basedontheregressionanalysis,bothCrCl
and age were found to be important pre-
dictors of metformin clearance. This study
did not provide evidence for speciﬁc
thresholds at which lactate production
may begin to rise.
These reports have relied on in-
formation derived from single doses of
metformin, which may not reﬂect chronic-
treatment pharmacokinetics. In contrast,
few reports have assessed the impact of
renal insufﬁciency on metformin clear-
ance during long-term use. Indeed, one
suchstudy(29)concludedthatmetformin
can be efﬁciently cleared in mild-to-
moderate CKD. In this investigation, 24
older patients (aged 70–88 years) were
administered metformin 850 mg/day or
1,700 mg/day based on CrCl of 30–60
mL/min (n = 11) or .60 mL/min (n = 13),
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remainedinthetherapeuticrangeandlac-
tate within the reference limits in all par-
ticipants. In addition, the measured levels
of metformin and lactate were not statisti-
cally different between those with and
without renal impairment (29).
Another recent study (30) evaluated
metformin levels in patients with type 2
diabetes and varying renal function. GFR
was estimated based on cystatin C levels.
The median dose of metformin was 1,500
mg/day. The median serum level of met-
formin was 4.5 mmol/L (~0.6 mg/mL)
(range 0.1–20.7) in patients with eGFR
.60 mL/min per 1.73 m
2 (n = 107), 7.7
mmol/L (~1.0 mg/mL) (0.1–15.2) with
eGFR 30–60 mL/min per 1.73 m
2 (n =
21), and 8.9 mmol/L (~1.1 mg/mL) (6.0–
18.6) with eGFR ,30 mL/min per 1.73
m
2 (n = 9). Notably, there were wide var-
iations in these levels within each group,
with few patients having serum levels
.20 mmol/L (.~2.6 mg/mL). However,
the “unsafe” metformin concentration is
not really known. At usual clinical doses
and schedules, steady-state plasma con-
centrationsaregenerally,1mg/mL(,7.8
mmol/L). Maximum plasma levels during
controlled clinical trials do not generally
exceed 5 mg/mL (38.8 mmol/L), but these
have not typically enrolled CKD patients.
Moreover,whethermeasurementofmet-
formin levels actually can aid in the pre-
diction of lactic acidosis risk remains
unclear. Therefore, although these stud-
ies provide some information on the re-
lationship between renal function and
metformin concentrations, they do not
clarify the issue of toxicity and lactic
acidosis risk.
Many of the early pharmacokinetic
studies with metformin actually relied on
CrCl based on 24-h urine collection for
creatinine. How well the current serum
creatinine cut points reﬂect the ability to
effectivelyclearthedrugalsoisunknown.
Creatinine levels, in general, vary in-
versely with GFR. However, important
limitations to the estimation of renal
function with creatinine should be con-
sidered. First, serum creatinine can only
be used reliably in patients with stable
kidney function. Second, variation in
creatinine production may differ among
and within individuals over time, espe-
cially if there are signiﬁcant changes in
muscle mass or in physical activity. Var-
iability in creatinine secretion, extrarenal
creatinine excretion, assay method, and
equipment can all affect serum measure-
ments. Calculated estimates (clearance
from the Cockroft-Gault and eGFR from
the Modiﬁcation of Diet in Renal Disease
equation) have been developed to incor-
porate known demographic and clinical
factors affecting serum concentrations.
These equations have their own inherent
shortcomings, such as residual limita-
tions with respect to age and race, un-
derestimation of GFR in the context of
diabetic renal disease (Cockroft-Gault
andModiﬁcationofDietinRenalDisease)
(31), and in obese individuals (Modiﬁca-
tion of Diet in Renal Disease) (32). How-
ever, they provide better estimation of
renal function than creatinine alone.
Moreover, development of new estimat-
ingequations,suchastheChronicKidney
Disease Epidemiology Collaboration
equation, may allow for even more accu-
rate estimates of renal function in the fu-
ture.Finally,dosingconsiderationsbythe
Food and Drug Administration for other
medications (e.g., sitagliptin, fenoﬁbrate)
are generally based on CrCl estimated
from such calculations and not on creati-
nine levels themselves.
LACTIC ACIDOSIS
ASSOCIATED WITH
METFORMIN THERAPY—Even
though elevated metformin concentra-
tions have been proposed to lead to lactic
acidosis, there are few data regarding the
level predisposing to hyperlactatemia. In
fact,multiplestudiessuggestthatelevated
circulating lactate levels, often attributed
to metformin, may actually not be caused
bythedrug.First,lacticacidosisoccursin
patients with type 2 diabetes more fre-
quently than in the general population; in
somereports,theobservedrateappearsto
besimilarinpatientsonmetforminversus
other glucose-lowering agents (11). Sec-
ond, metformin and lactate levels do not
necessarily appear to correlate, such that
higher metformin concentrations do not
consistently occur in those with more se-
vere degrees of lactic acidosis (33,34). Fi-
nally, metformin levels are not linked to
mortality in those who develop lactic ac-
idosis, perhaps reﬂecting the primary ef-
fectoftheunderlyingcauseoftheacidosis
(e.g., hypoxia, hemodynamic compro-
mise) on outcomes rather than incrimi-
nating metformin itself (33–35).
Although lactic acidosis remains a
recognized, albeit rare, adverse event
associated with metformin, the number
of lactic acidosis cases continues to be
very small, particularly when one consid-
ers the widespread use of this drug. In the
largest updated Cochrane meta-analysis,
Salpeter et al. (36) pooled data from 347
comparative trials and cohort studies.
Not a single case of lactic acidosis was
found in .70,000 metformin patient-
years or .55,000 nonmetformin person-
years. In this analysis, 53% of prospective
studiesallowedforinclusionofrenalinsuf-
ﬁciency, but patient-level serum creatinine
concentrations were not available for re-
view. Based on statistical inference, the es-
timated upper limit of true incidence was
4.3and5.4casesper100,000patient-years
in the metformin and nonmetformin
groups, respectively. This investigation
suggests that lactic acidosis is extremely
rare and the incidence does not differ in
those treated with metformin versus other
agents.
In a large, nested, case-control anal-
ysis of the U.K. general practice research
database (11), the crude incidence of lac-
ticacidosiswasevenlowerat3.3casesper
100,000 person-years among metformin
users and 4.8 cases per 100,000 person-
years among sulfonylurea users (in very
close agreement to the estimates of 3
and 2.4 cases per 100,000 patient-years
fromEurope andScandinaviabeforemet-
formin’s U.S.approval).Given allof these
ﬁndings, some (37) have argued that the
occurrence of lactic acidosis with metfor-
min use is merely coincidental and that
there is no tangible evidence from pro-
spective observational studies or clinical
trialsthatthedrugincreasesits incidence.
Of course, all these data have been col-
lected in the context of contemporaneous
strict metformin-prescribing guidelines.
It is possible that looser restrictions may
have led to more frequent occurrence of
lactic acidosis.
In summary, lactic acidosis remains
exceedingly rare in clinical trials and co-
hort studies of metformin therapy. More-
over,theavailabledatasuggestthatlactate
levels and risk of lactic acidosis do not
differ appreciably in patients taking this
versus other glucose-lowering agents.
Thus, the long-proclaimed causal rela-
tionship between metformin and lactic
acidosis remains in question.
CURRENT USE OF
METFORMIN IN CKD—Given the
current contraindications in the U.S.,
some might consider it a challenge to
conduct anew clinicaltrialtoevaluatethe
use of metformin in individuals with
various degrees of impaired renal func-
tion, taking into account new criteria for
assessing glomerular ﬁltration. Yet, evi-
dence suggests that metformin is often
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current labeling contraindications, pre-
scribed in full knowledge of the relevant
cutoffs (38–41). For example, in a review
(41) of restrictions to metformin therapy
conducted in Scotland, 24.5% of metfor-
minusershadﬁlledaprescriptiondespite
active contraindications (3.4% had the
speciﬁc local exclusion of a serum creati-
nine $1.7 mg/dL recorded twice on dif-
ferent days within 4 weeks). A single case
of lactic acidosis during 4,600 patient-
years of follow-up occurred in a patient
withanextensiveacutemyocardialinfarc-
tion who developed acute renal failure
and died the same day. Given the clinical
scenario, the authors intimated that aci-
dosis had occurred because of hemody-
namic compromise related to the infarct
and not to metformin accumulation. In a
U.S. study (42) performed in the primary
care practice setting, 4.5% of patients
treated with metformin had creatinine
levels .1.4 and 1.5 mg/dL in women and
men, respectively. Two other studies
(38,40) of sicker patients admitted to hos-
pitals in Germany and the U.S. conﬁrmed
high frequency of metformin use despite
various contraindications (73 and 27%,
respectively).
When one considers the imperfect
reﬂection of actual renal function by
serum creatinine, metformin is likely
used even more frequently in patients
with impaired GFR than that suggested
by the above studies. In the aforemen-
tioned U.S. primary practice setting,
where 4.5% of patients were given met-
formin despite creatinine-based contra-
indications, 17.7% of women and 13.4%
of men receiving metformin actually had
an abnormally low eGFR (#60 mL/min
per 1.73 m
2) (42). Likewise, in another
single U.S. center cross-sectional study
(43),15.3% ofpatients withtype2diabe-
tes and eGFR ,60 mL/min per 1.73 m
2
were receiving metformin. Such frequent
“inappropriate” use of metformin in pa-
tients is further suggested by data from
the National Health and Nutrition Exam-
inationSurvey(1999–2006)(43).Among
individuals with eGFR ,60 mL/min per
1.73m
2anddiabetes,32.2% were treated
with metformin and had a normal creati-
nine level (,1.5 mg/dL), whereas 13.4%
were treated with metformin despite a
frankly elevated creatinine level (.1.5
mg/dL). The use of metformin in mild-
to-moderate CKD clearly is not at all un-
common.
Two studies have attempted to trans-
late creatinine into corresponding eGFR
cut points in the context of metformin
therapy. In a review (44) of prescribing
practices in the U.K., appropriate use of
the drug was deﬁned on the basis of cre-
atinine level #1.7 mg/dL. Of 11,297 pa-
tients meeting those criteria, 82% had an
eGFR ,90, 25.5% ,60, and 2.8% ,30
mL/min per 1.73 m
2. The authors cal-
culated that the eGFR threshold of 36
mL/min would result in a similar number
of patients becoming ineligible for met-
formin compared with the serum creati-
nine threshold of 1.7 mg/dL (although
some patients would become newly eligi-
ble and some who previously qualiﬁed
would now become ineligible). The au-
thorsproposedthatifthecurrentpractice
is considered safe (and based on the re-
viewbySalpeteretal.[36],thisappearsto
beso),thenaswitchtoaneGFR-basedcut
point may be both a more practical and a
more accurate way to limit metformin ac-
cess in those with signiﬁcantly impaired
renal function. In another British study of
12,482 patients with diabetes, an eGFR
cutoff of 41 mL/min per 1.73 m
2 in men
and 30 mL/min per 1.73 m
2 in women
resulted in a similar proportion of pa-
tients having metformin withheld com-
pared with the serum creatinine threshold
of 1.7 mg/dL (45). The investigators there-
fore proposed the pragmatic eGFR limit
of 30 mL/min per 1.73 m
2 to denote abso-
lute contraindication to therapy.
Limited data speciﬁcallyaddressmet-
formin’s long-term safety in patients with
mild-to-moderate renal failure (46–48).
These studies found no increased risks
in various degrees of renal insufﬁciency
but were limited by small size and signif-
icant methodological shortcomings. Re-
cently, an analysis of the Reduction of
Atherothrombosis for Continued Health
Registry suggests that the proposed car-
diovascular beneﬁts of metformin may
extend to patients with established ath-
erosclerosis and moderate CKD (49).
In this large, observational study of
.19,000 subjects with a history of ath-
erothrombotic disease, 1,572 patients
were using metformin with eGFR 30–60
mL/minper1.73m
2.Afteradjustmentfor
baseline factors and propensity score,
metformin use was associated with a sig-
niﬁcant reduction in 2-year mortality in
the overall population (hazard ratio 0.76
[95% CI 0.65–0.89]), including in those
with moderate CKD (0.64 [0.48–0.86]).
However, lack of information with re-
spect to the duration of metformin use
and HbA1c,a sw e l la st h eo b s e r v a t i o n a l
nature of the study, require further
conﬁrmation of the mortality beneﬁt
in similar patient cohorts in prospective
trials.
Although these data are reassuring,
we must note that there are no random-
ized clinical trials that speciﬁcally evalu-
ated the safety of metformin use and
potential cardiovascular beneﬁts in pa-
tients with CKD.
PROGRESSION OF CKD IN
PATIENTS WITH DIABETES—Re-
nal function is dynamic, and renal
dysfunction in diabetes is typically pro-
gressive (50). Even in the absence of an
acute event, glomerular function slowly
declines with aging as nephron mass is
lost. The renal thresholds for the accept-
ability of metformin therapy should
therefore ideally account for the tempo
of CKD progression. The assessment of
renal function in clinical practice occurs
periodically, and the degree of renal dys-
function may change appreciably be-
tween these assessments. Therefore, it is
important to know how quickly GFR de-
clinesinthetypicalspectrumofnephrop-
athy among diabetic patients, particularly
when considering metformin therapy.
Few studies have, however, system-
atically evaluated the rate of progression
of renal dysfunction in the general di-
abeticpatientpopulationbydirectlymea-
suring GFR over time. Some data suggest
that eGFR tends to underestimate the rate
of GFR decline by as much as 28% when
compared with direct measurement (51).
Nevertheless, most of the available data
are based on estimations. A recent British
population-based cohort study (52) of
3,431 diabetic patients examined renal
decline as measured by changes in eGFR
(Modiﬁcation of Diet in Renal Disease).
The analysis of data collected over 7 years
demonstrated that the rate of progres-
sion was lowest among individuals who
were normoalbuminuric (0.3% or ~0.2
mL/min per 1.73 m
2 decline in eGFR per
year), intermediate in those with micro-
albuminuria (1.5% or ~1.2 mL/min per
1.73 m
2 per year), and highest in those
with macroalbuminuria (5.7% or 4.5
mL/min per 1.73 m
2 per year). In a large
Dutchstudy(53),eGFRfellby0.5mL/min
per 1.73 m
2 per year in the general pop-
ulationbuttoagreaterextentinthosewith
hypertension,diabetes,andmacroalbumin-
uria (1.9 mL/min per 1.73 m
2 per year).
Based on these and other results (31), av-
erageannualprogressionofrenaldysfunc-
tion in diabetes appears to be in the
range of 21t o24 mL/min per 1.73 m
2
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Metformin in renal insufﬁciencyof ﬁltration capacity, dependent in part
on other risk factors and the use of reno-
protective therapies. The decline is slow,
but, importantly, the majority of patients
in these studies had normal kidney func-
tionattheoutset.Thereislessinformation
availableon diabeticpatients with CKD. It
should also be noted that diabetes places
an individual at increased risk for other
causes of renal disease (54). Thus, all di-
abeticpatients,especiallythosewithCKD,
may be at risk for more rapid decline in
theirrenalfunctionoracutekidneyinjury.
Despite these appropriate concerns,
most of the available data would suggest
that, on average, eGFR declines slowly in
diabetes, although it can be accelerated to
some degree in the presence of albumin-
uria. If eGFR is calculated annually (and
more frequently in those at high risk for
deterioration in renal function), it is un-
likely that patients will experience
changes in their eGFR levels large enough
to rapidly alter the safety of metformin
therapy.
CONCLUSIONS AND
RECOMMENDATIONS—Although
metformin is eliminated renally, and ac-
cumulationmayconceivablyleadtolactic
acidosis, there currently is limited sys-
tematic evidence to substantiate contin-
ued reliance on the creatinine-based
contraindications in use in the U.S. In-
deed, in the modern era of eGFR, this
measure of glomerular ﬁltration appears
to give a more reliable estimate of renal
dysfunction. Metformin-associated lactic
acidosis is exceedingly rare based on the
available literature, and even though the
use of metformin has not been compre-
hensively assessed in individuals with
CKD, there is extensive evidence that
this agent often is used without adverse
effects in those with mildly to moderately
reduced renal function. In the context of
rising concerns regarding other glucose-
lowering therapies (55), safety restric-
tions over the use of metformin in this
population may result in the drug being
stoppedprematurelyandunnecessarilyin
some patients. This may lead to signiﬁcant
deterioration in glycemic control and/or
the need for other glucose-lowering medi-
cations, which present their own safety
concerns. An evidence-based approach
toprescribingmetformininthisgroupap-
pears warranted, taking into account the
current pervasive use of eGFR in clinical
care.
We therefore suggest that the current
guidelines for metformin use in the U.S.
be updated. These recommendations
should include eGFR thresholds that are
generally consistent with the National
Institute for Health and Clinical Excel-
lence guidelines in the U.K. and those
endorsed by the Canadian Diabetes As-
sociation and the Australian Diabetes
Society (Table 1). Metformin may be
continued (or initiated) with eGFR ,60
mL/min per 1.73 m
2, but renal function
should be monitored closely (every 3–6
months). The dose of metformin should
be reviewed and reduced (e.g., by 50% or
to half-maximal dose) in those with eGFR
,45mL/minper1.73m
2,andrenalfunc-
tion should be monitored closely (every
3 months). Metformin should not be ini-
tiated in patients at this stage, however.
The drug should be stopped once eGFR
falls to ,30 mL/min per 1.73 m
2.A d d i -
tional caution is required in patients with
anticipated signiﬁcant ﬂuctuations in re-
nal status or those at risk for abrupt de-
terioration in kidney function, based on
previous history, other comorbidities, al-
buminuria,andmedicationregimen(e.g.,
potent diuretics or nephrotoxic agents).
Without question, such a treatment
program could not be implemented with-
out meticulous clinical follow-up, clear
communication with patients regarding
risks and beneﬁts of therapy, and adher-
ence to frequent monitoring. The plan,
therefore, should be modiﬁed in patients
with suboptimal adherence to medical
instructions or regular follow-up. It is
clear that vigilance would be required so
that cases of lactic acidosis do not emerge
because of inappropriate use of metfor-
min in patients with more advanced and/
or unstable CKD.
Giventhefrequencywithwhichclini-
cians must decide whether to continue or
initiate metformin in mild-to-moderate
CKD, these recommendations would
have a profound impact on clinical prac-
tice. Such proposals, being consistent
with the sentiments of several well-
respected national guideline committees,
should be reviewed by professional med-
ical organizations in the U.S., such as the
American Diabetes Association. If a con-
sensus emerges, perhaps the Food and
Drug Administration might reconsider
the current metformin-prescribing guide-
lines, which, like those of other non-
branded compounds, tend to remain
static despite emerging evidence and
changes in clinical care.
In the future, more research in this
important area is needed, including pro-
spective, randomized trials of metformin
at varying degrees of renal impairment
and/or closer examination of registries of
CKD patients receiving metformin.
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